RNS Number:2619P
Medical Solutions PLC
02 September 2003


Immediate Release                                               2 September 2003


                              MEDICAL SOLUTIONS plc

                               BOARD STRENGTHENED


Medical Solutions plc ("the Company" or "Medical"), the cancer and pathology
services group, today announces the following appointments to the Board.  These
changes take immediate effect

Professor Karol Sikora (53), currently a Non-Executive Director of Medical, is
appointed to the Executive Board as Chief Scientific Director.  Professor Sikora
joined Medical in April 2002, prior to which he held a number of senior research
positions within the pharmaceutical industry.  These posts included: Vice
President of Global Clinical Research (Oncology) at Pharmacia Corporation;
Deputy Director of Clinical Research for the Imperial Cancer Research Fund;
Chief of the World Health Organisation and Clinical Director for Cancer Services
at Hammersmith Hospital, London.

Currently Professor Sikora is a Consultant to AstraZeneca; Special Adviser to
HCA Healthcare, the leading provider of healthcare services in America; Visiting
Professor of Cancer Medicine and honorary Consultant Oncologist at Imperial
College School of Medicine, Hammersmith Hospital, London.

Medical Solutions today also announces a second appointment - that of Dr Sue
Foden (50) who joins Medical as a Non-Executive Director.  Dr Foden has
significant experience in the healthcare market having been Chief Executive of
Cancer Research Campaign Technology Limited (1987-2000) and Cancer Research
Ventures Limited (1998-2000).

Dr Foden is currently a Venture Partner of Merlin Biosciences Limited, the
specialist life science investor trust.  As part of this role Dr Foden is a
Director of Ardana Bioscience Limited; BioVex Limited; De Novo Pharmaceuticals
Limited and PIramed Limited (all of whom Merlin Bioscience have an active
investment in).

Personally Dr Foden is a Director of the Institute of Cancer Research, Royal
Cancer Hospital, London; Cascade Fund Management Limited; NESTech Fund
Management Limited and Oxford Ancestors Limited, and is a member of the Wellcome
Trust's Technology Transfer Strategy  Panel.

Commenting on the appointments, Charles Green, Chief Executive of Medical
Solutions said,

"We are delighted to announce these two appointments today, both of which add
significant weight to our management team.  Professor Sikora has already proved
a great asset to the Board in his role as a Non-Executive and I am delighted
that he has decided to become a full-time member of the team.

I am also delighted that Dr Sue Foden has agreed to join Medical.  She has
immense experience and knowledge in the biotechnology and pharmaceutical markets
and I very much look forward to working with Sue in driving Medical forward."


For further information, please contact:

Medical Solutions
Charles Green, Chief Executive Officer                 Tel: +44 (0) 115 973 9010
Andy Longstaffe, Finance Director

Beattie Financial                                      Tel: +44 (0) 20 7398 3300
Mike Wort/ Ann-marie Wilkinson


Notes to Editors:

Medical Solutions plc provides world leading services and technology for cancer
diagnosis and pathology, supporting the Healthcare, Pharmaceutical and
Biotechnology sectors.

The group has two major divisions. The Services Division has a range of services
including Specialist Pathology, Biomaterials Resources and Expertise, and 5
Laboratories. These services are provided to the Pharma/Botech Industry
worldwide and to Healthcare providers, both public and private. The Technology
Divisions' range includes specialist imaging software for telemedicine, image
analysis and quantitation, and the SurePath liquid based cytology (smear test)
system. This division is also key in supporting its' Service divisions offerings
to both the Drug Development market and the Healthcare market.

The combination of world-renowned expertise, state of the art reference
laboratory facilities and innovative imaging technology puts Medical in a unique
position.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
BOALBMRTMMIMBFJ